The primary endpoint in AleNephro was met , indicating that in stage 3 chronic kidney disease patients with type 2 diabetes , the decrease in estimated glomerular filtration rate after 52 weeks ' treatment with aleglitazar followed by 8 weeks off-treatment was reversible and comparable ( non-inferior ) to pioglitazone .